Endpoints News 生物医药· Ryan Cross·· 28 天前AI 评分28
Alnylam 计划扩大 RNA 药物用于亨廷顿病的临床试验
Alnylam plans bigger study of RNA drug for Huntington’s disease
AI 导读
Alnylam 计划扩大 RNA 药物用于亨廷顿病的临床试验,基于 promising 生物标志物数据。该研究旨在评估药物在患者中的疗效和安全性。
正文
As with many of the most feared neurological conditions, Huntington’s disease has proven to be a minefield for drug developers. Promising biomarker data
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news